LXRX : Summary for Lexicon Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets closed

Lexicon Pharmaceuticals, Inc. (LXRX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.29+0.08 (+0.53%)
At close: 4:00PM EST

15.29 0.00 (0.00%)
After hours: 4:40PM EST

People also watch
ARRYFOLDHALOPGNXCYTK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close15.21
Open15.17
Bid13.00 x 100
Ask15.94 x 100
Day's Range15.01 - 15.37
52 Week Range8.37 - 19.62
Volume480,751
Avg. Volume685,673
Market Cap1.59B
Beta0.01
PE Ratio (TTM)-71.12
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Stocks We're Watching in the First Quarter
    Motley Fool7 days ago

    3 Stocks We're Watching in the First Quarter

    Our Foolish contributors are keeping a close eye on Bristol-Myers Squibb, Gilead Sciences, and Lexicon Pharmaceuticals in the first quarter of 2017.

  • PR Newswire9 days ago

    Lexicon To Present At The Leerink Partners 6th Annual Global Healthcare Conference

    THE WOODLANDS, Texas, Feb. 13, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) announced today that Lexicon management will present at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 3:30 p.m. Eastern Time in New York.  Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. Lexicon is a fully integrated biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for patients with serious, chronic conditions. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease.

  • Zacks21 days ago

    The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals

    The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals International, Celgene and Lexicon Pharmaceuticals